Back to medications
Medication monograph

tisagenlecleucel

Chimeric Antigen Receptor T-cell (CAR-T) TherapyAntineoplasticsImmunotherapy AgentsCD19-directed Chimeric Antigen ReceptorGenetically-modified Autologous T CellsGene Therapy

Clinical reference

Product monograph

KYMRIAH- tisagenlecleucel injection, suspension

Brands & formulations

Family members

KYMRIAH

Marketed
600000000 CELLSINTRAVENOUSSUSPENSION[ "tisagenlecleucel" ]
Product monograph

Classification

Chemical class
Chimeric Antigen Receptor T-cell (CAR-T) Therapy
Clinical class
Antineoplastics, Immunotherapy Agents
Banks class
CD19-directed Chimeric Antigen Receptor, Genetically-modified Autologous T Cells
AHFS family
Gene Therapy